ACCESS Pharmaceuticals is an oncology-focused targeted therapeutics company with a primary development focus is in the area of oncology with its polymer therapeutics program. The company's lead product, ProLindac, is in Phase II clinical development and is a polymer of DACH-platinum, the active principal of oxaliplatin (Eloxatin; Sanofi Aventis). The company's polymer therapeutics technology and extertise can be applied to other actives. The company has two technologies which it is currently seeking to outlicense. MuGard is a proprietary oral rinse formulation for the prevention and treatment of mucostis; an indication supported by clinical data. MuGard contains no pharmaceutically-active ingredient, and is regulated as a device in the US. A 510(k) application for US marketing approval is being prepared. In additional to MuGard's product potential, it could be formulated with actives which benefit from prolonged retention on mucosal surfaces. Access also has several patents and extensive data relating to the the use of certain vitamins to target drugs to the site of disease and/or facilitate absorption in the GI tract of actives which otherwise have poor oral bioavailability. Access is seeking partnerships to apply these technologies to improve targeting and/or solve oral bioavailability issues.

An integral part of the ACCESS business strategy is to form creative alliances with centers of excellence to obtain and/or develop lead compounds and technologies. The Company utilizes external resources including clinical opinion leaders, leading universities, contract research organizations and strategic partners to cost effectively develop the product opportunities. Once product candidates have concluded the early clinical development phase, it is the Company's strategy to out- license product candidates to larger pharmaceutical companies, which have both the expertise and resources to rapidly advance the development programs through the final clinical phase and ultimately maximize the products' revenue potential. This "semi-virtual company" strategy reduces the development, regulatory, financial and marketing risks, and is designed to generate superior financial returns in line with the pharmaceutical industry.